2015年内分泌代谢疾病主要进展

doi:10.3969/j.issn.1004-583X.2016.02.007

临床荟萃 ›› 2016, Vol. 31 ›› Issue (2): 162-167.doi: 10.3969/j.issn.1004-583X.2016.02.007

2015年内分泌代谢疾病主要进展

王绵,张力辉,苏胜偶

河北医科大学第二医院内分泌科, 河北石家庄 050000

收稿日期:2016-01-18 出版日期:2016-02-05 发布日期:2016-04-18
通讯作者: 王绵, Email: wangmian66@sina.com
作者简介:王绵,河北医科大学第二医院内分泌科副主任,博士,主任医师,三级教授,硕士生导师。现任中华预防医学会糖尿病预防与控制委员会委员,河北省医学会内分泌学分会常委兼秘书,河北省医学会内科学分会委员,河北省医学会内科医师分会委员。《临床荟萃》杂志编委。1988年毕业至今一直从事内分泌科的临床工作,积累了丰富的临床经验。发表论文60余篇,专著5部。获河北省卫生科技进步奖3项。

Clinical advances in endocrine and metabolic disease in 2015

Wang Mian, Zhang Lihui, Su Shenou

Department of Endocrinology, the Second Hospital of Hebei Medical University, Shijiazhuang 050000,China

Received:2016-01-18 Online:2016-02-05 Published:2016-04-18
Contact: Wang Mian, Email: wangmian66@sina.com

摘要/Abstract

摘要： 2015年的内分泌代谢领域发展迅速,精彩纷呈,不仅有很多重要指南更新或发布,也有很多热点临床研究结果出炉,涵盖了肥胖、糖尿病、甲状腺疾病、甲状旁腺疾病、肾上腺疾病及性腺疾病等,现就其中主要进展进行回顾和总结。

关键词: 肥胖症, 糖尿病, 甲状腺疾病, 甲状旁腺疾病, 肾上腺疾病, 性腺

Abstract: In 2015, development in the field of endocrine metabolism is rapid and colorful.Not only a lot of important guidelines have updated or issued, but also highlights in clinical research harvests much, covering the obesity, diabetes mellitus, thyroid disease, parathyroid disease, adrenal gland and gonad diseases, and others.The authors review and summarize the major progresses.

Key words: obesity, diabetes mellitus, thyroid diseases, parathyroid diseases, adrenal gland diseases, gonads

中图分类号:

王绵,张力辉,苏胜偶. 2015年内分泌代谢疾病主要进展[J]. 临床荟萃, 2016, 31(2): 162-167.

Wang Mian, Zhang Lihui, Su Shenou. Clinical advances in endocrine and metabolic disease in 2015[J]. Clinical Focus, 2016, 31(2): 162-167.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2016.02.007

https://huicui.hebmu.edu.cn/CN/Y2016/V31/I2/162

参考文献

[1] World Health Organization. Obesity and overweight. WHO fact sheet N°311 [EB/OL]. Geneva: WHO, 2015. www.who.int/mediacentre/factsheets/fs311/en/(last accessed November 30, 2015).
[2] World Health Organization. World Health Statistics 2015[EB/OL]. Geneva:WHO, 2015, pp101-111.www.who.int/gho/publications/world_health_statistics/2015/en/(last accessed November 30, 2015).
[3] Kelly T, Yang W, Chen CS, et al. Global burden of obesity in 2005 and projections to 2030[J]. Int J Obes (Lond),2008,32(9): 1431-1437.
[4] Hou X, Lu J, Weng J, et al. Impact of waist circumference and body mass index on risk of cardiometabolic disorder and cardiovascular disease in Chinese adults: a national diabetes and metabolic disorders survey[J]. PLoS One, 2013, 8(3):e57319.
[5] Tian Y, Wu H. Prevalence of obesity among students aged 6 to 12 in China: a meta-analysis[J]. Food Nutr Res, 2015,17(59):25747.
[6] Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab,2015, 100(2): 342-362.
[7] Yumuk V, Tsigos C, Fried M, et al. European Guidelines for Obesity Management in Adults[J]. Obes Facts,2015, 8(6):402-424.
[8] Toplak H, Woodward E, Yumuk V, et al. 2014 EASO Position Statement on the Use of Anti-Obesity Drugs[J]. Obes Facts, 2015, 8(3):166-174.
[9] Stegenga H, Haines A, Jones K,et al.Identification, assessment, and management of overweight and obesity: summary of updated NICE guidance[J]. BMJ,2014, 349:g6608.
[10] Rao G, Powell-Wiley TM, Ancheta I, et al. Identification of obesity and cardiovascular risk in ethnically and racially diverse populations: a scientific statement from the American Heart Association[J]. Circulation,2015, 132(5): 457-472.
[11] Practice Committee of the American Society for Reproductive Medicine. Obesity and reproduction: a committee opinion[J]. Fertil Steril,2015, 104(5): 1116-1126.
[12] 中华医学会糖尿病学分会. 中国血糖监测临床应用指南(2015年版)[J].中华糖尿病杂志,2015, 7(10): 603-613.
[13] 陈莉明. 见微知著,引领未来解读2015中国血糖监测临床应用指南[J]. 中华糖尿病杂志, 2015, 7(10): 593-596.
[14] American Diabetes Association. Standards of medical care in diabetes— 2015[J]. Diabetes Care,2015, 38 (Suppl 1):S1-S93.
[15] Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American association of clinical endocrinologists and american college of endocrinology-clinical practice guidelines for developing a diabetes mellitus comprehensive care plan-2015[J]. Endocr Pract, 2015, 21(Suppl 1):1-87.
[16] Garber AJ, Abrahamson MJ, Barzilay JI, et al. Aace/Ace comprehensive diabetes management algorithm 2015[J]. Endocr Pract, 2015, 21(4): 438-447.
[17] Fox CS, Golden SH, Anderson C, et al. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association[J]. Circulation,2015, 132(8): 691-718.
[18] Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes[J]. Diabetes Care, 2015, 38(1):140-149.
[19] 中华医学会糖尿病学分会微血管并发症学组. 糖尿病肾病防治专家共识(2014年版)[J]. 中华糖尿病杂志,2014, 6(11): 792-801.
[20] Bakker K, Apelqvist J, Lipsky BA, et al. The 2015 IWGDF guidance documents on prevention and management of foot problems in diabetes: development of an evidence-based global consensus[J]. Diabetes Metab Res Rev,2015 Sep 27. [Epub ahead of print]
[21] The IWGDF Working Group on Foot Infection. IWGDF guidance on the diagnosis and management of foot infections in persons with diabetes[EB/OL].[2015 06 06]. http://www. iwgdf.org/files/ 2015 / website_infection.pdf.
[22] 许樟荣. 《国际糖尿病足工作组关于糖尿病足感染的诊断与处理指南》解读[EB/OL]. 中华糖尿病杂志, 2015,7(7): 403-404.
[23] Internal Clinical Guidelines team. Diabetic Foot Problems: Prevention and Management. London: National Institute for Health and Care Excellence (UK)[S]. 2015 Aug.
[24] Lavery LA, Davis KE, Berriman SJ, et al. WHS Guidelines Update: Diabetic Foot Ulcer Treatment Guidelines[J]. Wound Repair Regen, 2015 Dec 9. [Epub ahead of print]
[25] Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes[J]. N Engl J Med,2015, 373(22): 2117-2128.
[26] Zinman B, Inzucchi SE, Lachin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME)[J]. Cardiovasc Diabetol, 2014, 13: 102.
[27] Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2015, 373(3): 232-242.
[28] Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome[J]. N Engl J Med,2015, 373(23): 2247-2257.
[29] Hayward RA, Reaven PD, Wiitala WL, et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med,2015, 372(23): 2197-2206.
[30] An Y, Zhang P, Wang J, et al. Cardiovascular and all-cause mortality over a 23-year period among Chinese with newly diagnosed diabetes in the Da Qing IGT and Diabetes Study[J]. Diabetes Care, 2015, 38(7):1365-1371.
[31] Unger RH, Scherer PE, Holland WL. Dichotomous roles of leptin and adiponectin as enforcers against lipotoxicity during feast and famine[J]. Mol Biol Cell, 2013, 24(19): 3011-3015.
[32] Xia JY, Holland WL, Kusminski CM, et al. Targeted induction of ceramide degradation leads to improved systemic metabolism and reduced hepatic steatosis[J]. Cell Metab,2015, 22(2):266-278.
[33] Kajimura S, Spiegelman BM, Seale P, et al. Brown and Beige fat: physiological roles beyond heat generation[J].Cell Metab,2015, 22(4): 546-559.
[34] Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer[J]. Thyroid, 2016, 26(1): 1-133.
[35] Francis GL, Waguespack SG, Bauer AJ, et al. Management guidelines for children with thyroid nodules and differentiated thyroid cancer[J]. Thyroid,2015, 25(7): 716-759.
[36] Bollerslev J, Rejnmark L, Marcocci C, et al. European Society of Endocrinology Clinical Guideline: treatment of chronic hypoparathyroidism in adults[J]. Eur J Endocrinol, 2015, 173(2):G1-G20.
[37] Nieman LK, Biller BM, Findling JW, et al. Treatment of Cushing's syndrome: an endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab,2015, 100(8):2807-2831.
[38] 中华医学会内分泌学分会性腺学组. 特发性低促性腺激素性性腺功能减退症诊治专家共识[J]. 中华内科杂志,2015, 54(8):739-744.
[39] Boehm U, Bouloux PM, Dattani MT, et al. Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism-pathogenesis, diagnosis and treatment[J]. Nat Rev Endocrinol,2015, 11(9): 547-564.

2015年内分泌代谢疾病主要进展

Clinical advances in endocrine and metabolic disease in 2015

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	吕莎莎, 宋金兰, 石健. m.3243A>G突变相关线粒体糖尿病1例并文献复习[J]. 临床荟萃, 2024, 39(2): 160-163.
[2]	张佳楠, 孙琳琳, 詹潇燕, 李冰. 血清维生素B₁₂与老年2型糖尿病轻度认知功能障碍的关系[J]. 临床荟萃, 2024, 39(1): 34-37.
[3]	伊鹏, 李翠玲, 黄新疆, 曾春华. 促性腺激素释放激素类似物治疗下丘脑错构瘤导致性早熟5例临床分析[J]. 临床荟萃, 2024, 39(1): 53-56.
[4]	位增, 曹灵, 佘敦敏, 刘彦, 王艳, 张真稳. 54例2型糖尿病患者合并新型冠状病毒感染的死亡原因分析[J]. 临床荟萃, 2023, 38(9): 806-812.
[5]	张娜文, 黄少敏, 田利民. 2型糖尿病与帕金森病相关性研究的进展[J]. 临床荟萃, 2023, 38(9): 845-850.
[6]	杨鑫, 许华娇. 基于Web of Science糖尿病患者心理干预研究的文献计量学分析[J]. 临床荟萃, 2023, 38(8): 731-736.
[7]	马光宇, 罗慧娟, 王冬菊, 肖小敏. 黄芩苷治疗糖尿病及其并发症的研究进展[J]. 临床荟萃, 2023, 38(8): 757-762.
[8]	张欣欣, 刘国庆, 王蓓蓓. 糖尿病酮症酸中毒引起极度血小板增多症1例并文献复习[J]. 临床荟萃, 2023, 38(8): 719-721.
[9]	金家辉, 杨阳, 秦铜, 何雨欣, 苏美华. 补充益生菌对2型糖尿病患者糖代谢改善的meta分析[J]. 临床荟萃, 2023, 38(7): 581-587.
[10]	谢新荣, 甘精华, 覃睿, 钟慕贤. 雄激素受体不敏感综合征合并绒癌及人绒毛膜促性腺激素相关甲亢1例并文献复习[J]. 临床荟萃, 2023, 38(7): 628-632.
[11]	马芙蓉, 白晋瑜, 徐翔宇, 陈慧. Klinefelter综合征1例并文献复习[J]. 临床荟萃, 2023, 38(6): 537-540.
[12]	贾丽娜, 吴美妮, 尹昌浩. 2型糖尿病认知功能障碍发病机制的研究进展[J]. 临床荟萃, 2023, 38(6): 554-558.
[13]	陈婷, 刘金彦. 中药靶向PI3K/Akt/mTOR通路调节自噬在糖尿病肾脏病中的研究进展[J]. 临床荟萃, 2023, 38(6): 564-568.
[14]	苏晨蓓, 王富军. 糖尿病下肢动脉疾病介入治疗疗效的研究进展[J]. 临床荟萃, 2023, 38(6): 569-572.
[15]	吴亚楠, 延天美, 梁鹏, 魏立民. 中老年糖尿病患者抑郁症状的高危识别[J]. 临床荟萃, 2023, 38(6): 516-520.